United Kingdom experience with alendronate and oesophageal reactions

British Journal of General Practice

Volumn 48, Issue 429, 1998, Pages 1161-1162

  Mackay, F J ^a   Wilton, L V ^a   Pearce, G L ^a   Freemantle, S N ^a   Mann, R D ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Oesophageal disease; Osteoporosis; Prescription event monitoring

Indexed keywords

ALENDRONIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; DRUG MONITORING; DYSPEPSIA; ESOPHAGITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; UNITED KINGDOM; VOMITING;

AGED; ALENDRONATE; ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0031894591     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-1021.
2. Mann RD, Wilton LV, Pearce GL, et al. Prescription-event monitoring (PEM) in 1996 - a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Safety 1997; 6 (suppl.3): 5-11.
3. McAvoy BR, Kaner EFS. General practice postal surveys: a questionnaire too far? BMJ 1996; 313: 732-733.
4. Faich GA. US Adverse Drug Reaction Surveillance 1989-1994. Pharmacoepidemiol Drug Safety 1996; 5: 393-398.
5. Monthly Index of Medical Specialties. 1996; May: 12.
6. Important Safety Information. Fosamax (alendronate sodium) - oesophageal reactions. Merck Sharp & Dohme Ltd, April 1996.